| Condition | Key Finding | Association | Board Exam Tip |
| Graves' Disease | Low TSH, High T3/T4, Diffused RAIU uptake | Autoantibodies are TSH receptor agonists | Remember that the antibodies stimulate the gland, unlike destructive thyroiditis. |
| Hereditary Spherocytosis | Elevated indirect bilirubin; positive osmotic fragility test | Defect in cytoskeletal proteins (spectrin, ankyrin) | The spleen is responsible for removing these unstable RB Cs, leading to hemolysis. |
| SIADH | Hyponatremia + High Urine Osmolality | ADH excess/action on V2 receptors | Always check the urine osmolality; high U Osm rules out CDI and suggests water retention. |
| Cyclosporine Toxicity | Hypertension, Hyperkalemia, Type 4 RTA | Constriction of afferent arteriole -> RAAS activation + Aldosterone suppression | The combination of HTN/Hyperkalemia is highly suggestive of calcineurin inhibitor toxicity. |
| Topic | Key Point | Context | Exam Relevance |
| Graves' Disease | TSH receptor agonists (autoantibodies) | Hyperthyroidism; Diffused uptake on RAIU scan | High-yield diagnosis requiring specific lab pattern recognition and appropriate anti-thyroid drug choice. |
| Hereditary Spherocytosis | Cytoskeletal protein defects (Spectrin, Ankyrin) | Hemolytic anemia; Positive osmotic fragility test | Requires understanding the underlying structural defect rather than just recognizing spherocytes. |
| SIADH vs CDI | SIADH: {U}_{{osm}} > {S}_{{osm}} / Hyponatremia. CDI: {U}_{{osm}} < {S}_{{osm}} / Hypernatremia. | Water balance disorders; ADH excess vs deficiency. | The urine osmolality is the single most critical differentiating lab test. |
| Cyclosporine Toxicity | HTN, hyperkalemia, Type 4 RTA | Calcineurin inhibitor use (transplant); RAAS activation and aldosterone suppression. | A classic drug-induced renal complication that tests understanding of mineralocorticoid axis regulation. |
| Board-speak / Vignette phrase | Diagnosis / Concept | Why it fits |
| A 39 y/o female with palpitations, tachycardia (HR 125), and an EKG showing an irregularly irregular rhythm. | Hyperthyroidism (Graves' Disease) | Tachycardia and Afib are common manifestations; the irregular rhythm is classic for Atrial Fibrillation. |
| A patient with chronic anemia, multiple family members affected, elevated indirect bilirubin, and a positive osmotic fragility test. | Hereditary Spherocytosis | The combination of inherited hemolytic anemia, spherocytes (membrane defect), and increased indirect bilirubin points directly to HS. |
| Hyponatremia found in a patient who recently had meningitis or Pneumocystis pneumonia. | Syndrome of Inappropriate ADH Release (SIADH) | Meningitis/CNS injury can cause SIADH; the presence of an underlying lung infection is a common trigger for inappropriate ADH release. |
| A kidney transplant recipient develops hypertension, headaches, and hyperkalemia. | Cyclosporine Toxicity | Cyclosporine constricts the afferent arteriole (leading to RAAS activation/HTN) and suppresses aldosterone synthesis, causing hyperkalemia and Type 4 RTA. |
| A patient with PCOS who is obese presents with endometrial hyperplasia risk. | Estrogen Excess / Endometrial Hyperplasia | Chronic anovulation leads to unopposed estrogen from the ovaries; obesity adds systemic estrogen via aromatase activity in adipose tissue. |
| Key Features | Distinguishing Findings | Next Step |
| Hereditary Spherocytosis | Defect in cytoskeletal proteins; Positive osmotic fragility test; Spherocytes on smear. | Splenectomy (if severe); Transfusion/Bilirubin management. |
| Autoimmune Hemolytic Anemia (AIHA) | Warm autoantibodies against RB Cs; Positive Coombs test. | Immunosuppression (Steroids, Rituximab). |
| Condition | Association | Mechanism | Clinical Significance |
| Graves' Disease | TSH receptor agonists (autoantibodies) | Stimulates thyroid hormone production; causes diffuse uptake. | Requires specific anti-thyroid drugs or I-131 therapy for definitive management. |
| Hereditary Spherocytosis | Cytoskeletal protein defects (Spectrin, Ankyrin) | Leads to unstable RBC membranes and splenic phagocytosis. | The diagnosis is confirmed by the positive osmotic fragility test and spherocyte morphology. |
| SIADH | ADH excess/action on V2 receptors | Increased free water reabsorption in collecting duct principal cells. | Causes dilutional hyponatremia; requires fluid restriction as primary treatment. |
| Cyclosporine Toxicity | Hyperkalemia / Type 4 RTA | Suppression of aldosterone synthesis from the zona glomerulosa. | A critical drug-induced complication that must be monitored post-transplant. |
| Term | Definition | Context | Example |
| TSH receptor agonist | An antibody that mimics TSH and stimulates the thyroid gland. | Graves' disease pathophysiology. | Autoantibodies causing hyperthyroidism; leads to high {T}_3/{T}_4 and low TSH. |
| Cytoskeletal proteins | Proteins providing structural support to cell membranes, particularly RB Cs. | Hereditary Spherocytosis. | Spectrin and ankyrin defects lead to membrane instability and hemolysis. |
| Desmopressin ({DDAVP}) | Synthetic analog of ADH (vasopressin). | Treatment for Central Diabetes Insipidus (CDI). | Used when the kidney cannot respond to endogenous ADH; risk is inducing hyponatremia. |
| Aromatase | Enzyme that converts androgens to estrogens. | PCOS/Obesity-related estrogen excess. | Adipocytes expressing aromatase contribute extra estrogen, worsening endometrial hyperplasia risk. |
| Topic | Study Approach | Priority | Resources |
| Endocrine Emergencies | Focus on the mechanism of imbalance (e.g., why hyperkalemia occurs with cyclosporine). | High | Review drug side effects and hormonal axes (RAAS, TSH axis). |
| Renal Tubular Physiology | Master the differential diagnosis based on urine osmolality ({U}_{{osm}}) and serum electrolytes. | Medium-High | Use flowcharts: {Na}^+ level -> Urine output/Osmolality -> Diagnosis. |
| Hematology Defects | Understand the structural basis of the defect (cytoskeleton, membrane). | High | Memorize key proteins (Spectrin, Ankyrin) and associated tests (Osmotic Fragility). |
🚫Mistake 2: Misattributing Hyperkalemia. Do not assume hyperkalemia always means primary adrenal failure. It can be drug-induced (e.g., cyclosporine) by suppressing aldosterone synthesis, even if the RAAS system is activated.
⚠️Trap 3 (Cyclosporine/RAAS): The question may emphasize RAAS activation leading to HTN, but the hyperkalemia is due to aldosterone suppression at the adrenal level, not just volume expansion.